Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Clin Cancer Res. 2015 May 26;21(17):3995–4003. doi: 10.1158/1078-0432.CCR-14-2728

Figure 2. ER and Bcl2 changes upon neoadjuvant treatment with lapatinib.

Figure 2

A. Each line represents changes in ER expression levels from baseline to week 2. ER levels are expressed as Allred scores. Solid red lines indicate tumors with ER-positive status at baseline (Allred score ≥ 3); dashed red lines indicate those three tumors that were ER-negative at baseline (Allred score < 3) and became positive at week 2; solid black lines indicate tumors with ER-negative status at baseline that remained negative at week 2 (14 tumors).

B. Each line represents Bcl2 expression changes from baseline to week 2. Bcl2 levels are expressed as percentage of positive cells. Solid red lines indicate Bcl2 changes in the 6 tumors with ER-positive status at baseline; dashed red lines indicate Bcl2 changes in the 3 tumors converting from ER-negative to positive; solid black lines indicate Bcl2 changes in the 14 tumors that were ER-negative at both baseline and week 2.

C. Percentage of tumors with a Bcl2 increase over time, according to ER status. Bcl2 increased at week 2 in 8 out of 9 of the ER-positive tumors, (including the 3 tumors converting to ER-positive), and in 1 out the 14 tumors that remained ER-negative.